Requires health insurance carriers to cover genetic testing after diagnosis of pancreatic cancer.
Summary
Assembly Bill 4699 requires a broad set of New Jersey health coverage arrangements to pay for genetic testing when a covered person has been diagnosed with pancreatic adenocarcinoma. The mandate applies to hospital service corporation contracts, medical service corporation contracts, health service corporation contracts, individual and group health insurance policies, individual and small employer health benefits plans, HMO enrollee agreements, and contracts purchased by the State Health Benefits Commission and School Employees’ Health Benefits Commission. Coverage must be provided to the same extent as for other medical conditions under the applicable contract or plan.
The bill defines genetic testing broadly to include tests analyzing DNA, RNA, chromosomes, or proteins to identify mutations associated with pancreatic adenocarcinoma and other cancers, and to guide monitoring, treatment decisions, and appropriate management. The definition expressly includes germline testing and tumor molecular profiling. The act would take effect on the first day of the fourth month after enactment and would apply to policies and contracts delivered, issued, executed, or renewed on or after that date.
Impact
The bill would amend and supplement multiple New Jersey insurance statutes by creating a specific post-diagnosis coverage requirement for pancreatic adenocarcinoma genetic testing across both commercial and public employee health coverage. It would affect insurers, health service corporations, hospital service corporations, medical service corporations, HMOs, and administrators of the State Health Benefits Program and School Employees’ Health Benefits Program, requiring them to treat this testing as a covered benefit when medically indicated after diagnosis. The practical effect is to expand mandated health benefits and limit the ability of carriers to exclude or restrict payment for these tests in covered plans.
Sentiment
No committee transcripts or recorded votes were provided, so there is no direct evidence of debate or formal support/opposition in the available materials. Based on the bill text and sponsor statement, the measure appears to be framed as a patient-access and cancer-care coverage bill, with an emphasis on ensuring medically necessary genetic testing is available after a pancreatic cancer diagnosis. The overall tone of the legislation is protective and health-care oriented, with no visible indication of partisan or procedural controversy in the supplied record.
Contention
The main policy issue likely to arise is the cost and scope of the insurance mandate, particularly because the bill requires coverage across many plan types and public programs and defines genetic testing broadly to include germline testing and tumor molecular profiling. Insurers and plan administrators could be concerned about premium impacts, utilization, and administrative complexity, while patient advocates and clinicians would likely support the mandate as a way to improve treatment planning and access to precision medicine. Another possible point of discussion is the bill’s focus on pancreatic adenocarcinoma specifically, rather than creating a broader genetic-testing mandate for other cancers or conditions.